SPARC drops as Q2 net loss widens to Rs 107 crore
Sun Pharma Advanced Research Company (SPARC) slipped 5.09% to Rs 205.10 after the company reported net loss of Rs 107.28 crore in Q2 FY25 as compared with net loss of Rs 86.08 crore in Q2 FY24.
Net sales declined 39.29% year on year (YoY) to 12.86 crore in the quarter ended 30 September 2024.Total expenses rose 3.43% YoY to Rs 120.07 crore in September 2024 quarter.
Employee benefit expenses stood at Rs 38.48 crore (up 25.3% YoY), professional charges were at Rs 30.75 crore (down 26.58% YoY), clinical trial expenses at Rs 25.53 crore (up 40.2% YoY).
On half yearly basis, the firm reported net loss of Rs 204.44 crore in H1 FY25 as against net loss of Rs 181.09 crore in H1 FY24. Net sales decreased 34.26% YoY to Rs 29.67 crore in H1 FY25.
Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Nov 04 2024 | 5:01 PM IST